Related Experiment Video

Updated: Sep 25, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

[Effectiveness of pre- and postprandial Humalog in adolescents with type 1 diabetes]

B Florys, J Peczyńska, M Urban

    Endokrynologia, Diabetologia I Choroby Przemiany Materii Wieku Rozwojowego : Organ Polskiego Towarzystwa Endokrynologow Dzieciecych
    |June 24, 2003
    PubMed

    Insights

    Administering Humalog insulin after meals in adolescents with type 1 diabetes offers good glucose control and safety. This approach improves quality of life without increasing hypoglycemia risk.

    Area of Science:

    • Endocrinology
    • Metabolic Disorders
    • Pharmacology

    Context:

    • Type 1 diabetes management in adolescents.
    • Evaluating rapid-acting insulin efficacy.
    • Glycemic control strategies.

    Purpose:

    • To assess the glycemic response to pre- and postprandial Humalog administration in type 1 diabetic adolescents.
    • Compare the efficacy and safety of Humalog given before versus after meals.
    • Evaluate impact on HbA1c and hypoglycemic episodes.

    Summary:

    • A 3-month study in 47 adolescents (ages 12-18) with type 1 diabetes compared pre- vs. postprandial Humalog. Both groups showed similar glycemic control and HbA1c reduction (8.01% to 7.63%). Postprandial administration resulted in fewer mild hypoglycemic events.
    • Patients receiving Humalog postprandially demonstrated comparable glycemic control to those receiving it preprandially, with a statistically significant reduction in mild hypoglycemic episodes (0.19 vs. 0.32 episodes/person/day).

    Impact:

    • Postprandial Humalog administration is a safe and effective strategy for managing type 1 diabetes in adolescents.
    • Flexibility in Humalog timing allows for better matching of insulin doses to food intake, enhancing patient quality of life.
    • Findings support individualized insulin therapy regimens to optimize glycemic control and minimize adverse events.
    Abstract

    Related Concept Videos

    Insulin: Dosing Regimen and Adverse Effects01:16

    Insulin: Dosing Regimen and Adverse Effects

    Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
    The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
    Insulin Formulations: Types and Delivery01:27

    Insulin Formulations: Types and Delivery

    Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
    Short-acting insulins are divided into rapid-acting...
    Oral Hypoglycemic Agents: Glinides01:06

    Oral Hypoglycemic Agents: Glinides

    Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
    Diabetes Mellitus: Overview and Type I Subtype01:22

    Diabetes Mellitus: Overview and Type I Subtype

    Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
    Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
    Hypoglycemia and Glucagon01:15

    Hypoglycemia and Glucagon

    Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...